NASDAQ$TCRX
Tscan Therapeutics Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported full year 2021 financial results and highlighted key 2022 priorities.
TScan Therapeutics reported its full year 2021 financial results, highlighting FDA clearance of IND for TSC-100, the upcoming initiation of a Phase 1 trial for the liquid tumor program, and a strong balance sheet with $161.4 million in cash and cash equivalents.
- Received FDA clearance of IND for TSC-100 for hematologic malignancies treatment.
- Phase 1 umbrella trial for liquid tumor program is expected to start in H1 2022, with preliminary data anticipated in H2 2022.
- Two INDs for the TSC-200 series are expected by the end of the year.
- The company reported a strong financial position, with $161.4 million in cash and cash equivalents as of December 31, 2021, which is expected to fund operations into 2024.
Headline financials
Revenue & EPS history
Tscan Therapeutics · Revenue · Quarterly
$2.85M
Revenue by segment
Tscan Therapeutics · $10.1M total across 1 segment · Q4 2021
- Collaboration & License$10.1M—100.0%
Forward guidance
TScan Therapeutics is focused on advancing its liquid and solid tumor programs, with key milestones expected in 2022, including initiating a Phase 1 trial for TSC-100, presenting preclinical data on the TSC-200 series, and submitting two IND applications.
Tailwinds
- Initiate Phase 1 umbrella trial for TSC-100 in H1 2022.
- Present initial clinical data from the liquid tumor program in H2 2022.
- Present initial preclinical data on the TSC-200 series in H1 2022.
- Submit two IND applications for the TSC-200 series in H2 2022.
- Continue research into potential T cell focused COVID-19 vaccine constructs.
Headwinds
- FDA placed a clinical hold on the IND for TSC-101 in January 2022.
- The company is working with the FDA to resolve questions regarding potential off-tumor reactivity of TSC-101.
- Resolution of the clinical hold on TSC-101 is necessary to open the TSC-101 arm of the ongoing trial.
- Success of clinical trials and preclinical studies is subject to risks and uncertainties.
- The COVID-19 pandemic could affect TScan's business and operations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
+1.6%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-5.7%
Avg return
30 days after
60%
12 / 20 earnings
Positive
+32.4%
Q1 2023
Best reaction
-18.2%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.3% | -3.3% | -18.9% | |
| Q4 2025 | +4.9% | +19.8% | -2.4% | |
| Q3 2025 | +0.8% | -20.5% | -17.2% | |
| Q2 2025 | +3.1% | +11.8% | +14.9% | |
| Q1 2025 | -4.6% | +0.8% | +18.3% | |
| Q4 2024 | +2.6% | +7.7% | -7.1% | |
| Q3 2024 | -7.9% | -22.6% | -47.0% | |
| Q2 2024 | -1.0% | -3.0% | -3.9% | |
| Q1 2024 | +16.3% | +16.2% | +14.9% | |
| Q4 2023 | +1.6% | -6.7% | +0.9% | |
| Q3 2023 | +3.0% | +14.9% | +50.8% | |
| Q2 2023 | -4.2% | -2.3% | +12.1% | |
| Q1 2023 | +32.4% | +18.5% | -14.4% | |
| Q4 2022 | -8.5% | -23.0% | -33.3% | |
| Q3 2022 | -0.4% | +3.9% | -20.6% | |
| Q2 2022 | -10.8% | -18.8% | -20.5% | |
| Q1 2022 | +10.6% | +38.3% | +80.0% | |
| Q4 2021 | +7.8% | -1.6% | -37.8% | |
| Q3 2021 | +2.2% | -4.4% | -28.0% | |
| Q2 2021 | -18.2% | -21.7% | -53.7% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro